Research Article | Open Access | 10.31586/Microbiology.0403.02
Epstein - Barr Virus Capsid Antigen (EBV-VCA) IgM Antibodies among HIV Infected Individuals in Jos, Nigeria.
Received January 23, 2019
Revised February 23, 2019
Accepted February 27, 2019
Published March 1, 2019
AbstractHuman immunodeficiency virus (HIV) infection is associated with an increased risk for Viral infections such as Epstein-Barr virus (EBV)infections also known as Human Herpes Virus Type 4 (HHV-4) and their related diseases which frequently cause malignancy related diseases resulting to poor treatment and health outcomes. In this study, we determined the seroprevalence of EBV VCA IgM antibodies among HIV patients attending Plateau Specialist Hospital, Jos, Nigeria and to evaluate their association with age, sex as well as other demographic factors. A total of 92 HIV positive patients were enrolled and serum samples were screened for antibodies using the ELISA kit. The prevalence of EBV VCA IgM was 6/92(6.53%), and mean age of 37.48 ±1.01 years. This study has contributed to baseline data, and suggest the need for larger studies and importance of screening and treatment of EBV among HIV patients.
Balfour HHJr, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6–19 years in the United States and factors affecting its acquisition. J Infect Dis, 2013; 208: 1286–1293
Rickinson AB, Kieff E. Epstein-Barr virus. In: Virology (eds. DM Knipe, PM Howly) 5th ed., Vol. 2, Wolters Kluwer /Lippincott Williams & Wilkins, Philadelphia, 2006; pp. 2655-2700.
Cohen JI. Epstein-Barr virus infection. N Engl J Med, 2000; 343: 481–492.
Tsai MH, Hsu CY, Yen MH, Huang YC, Lin SJ, Lin TY et al. Epstein-Barr virus-associated infectious mononucleosis and risk factor analysis for complications in hospitalized children. J Microbiol Immunol Infect, 2005; 38: 255–261
Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, Morishima T. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood, 2001; 98: 280–286
Chen CJ, Huang YC, Jaing TH, Yang CP., Chang LY, Lin TY et al. Hemophagocytic syndrome: a review of 18 pediatric cases. J Microbiol Immunol Infect, 2004; 37: 157–163
Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Virus Research, 2009; 143, 209-221.
Thorley-Lawson, D.A., Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med, 2004; 350: 1328–1337.
Bertrand AK, Birmann MB, Chang ET, Spiegelman D, Aster J C, Laden F et al. A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma. Blood, 116 2010; 3547-3553
Kangro HO, Osman HK, Lau YL, Heath RB, Yeung CY, Ng MH. Seroprevalence of antibodies to human herpesviruses in England and Hong Kong. J Med Virol, 1994; 43: 91–96.
Dowd JB, Palermo T, Brite J, McDade TW, Aiello A. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6–19, 2003–2010. PLoS One, 2013; 8: e64921.
Bishop GH, Adegoke OO. Seroprevalence of Epstein-Barr Virus IgM Antibodies among HIV-Patients and Apparently Healthy Blood Donors Attending Ahmadu Bello University Teaching Hospital, Shika-Zaria, Nigeria. International Journal of Scientific Research in Knowledge, 2016; 4(5): 105-111
Kolawole OE, Kola OJ, Elukunbi AH. Detection of Epstein-Barr virus IgM in HIV infected individuals in Ogbomoso, Nigeria. British Journal of Virology, 2017; 3(6): 177-182.
Ibrahim MH, Faten R, Abdel Ghaffar ARF, El Shaer ER, Madian AM. Prevalence of Epstein-Barr Virus and Hepatitis B Virus Infections among Chronic HCV PatientsAttending Kafer El Shiekh Liver and Heart Institute, Egypt. Journal of Advances in Medicine and Medical Research (JAMMR), 2018; 26(8): 1-8,
Chen CY, Huang KYA, Shen J-H, Tsao K-C, Huang Y-C. A Large-Scale Seroprevalence of Epstein-Barr Virus in Taiwan. PLoS ONE, 2015; 10(1): e0115836.
Higgins CD, Swerdlow AJ, Macsween KF, Harrison N, Williams H, Crawford A et al. Study of risk factors for acquisition of Epstein-Barr virus and its subtypes. J Infect Dis. 2007; 195(4):474-82.
Crawford DH, Swerdlow AJ, Higgins C, McAulay K, Harrison N, Williams H et al. Sexual history and Epstein-Barr virus infection. Infect. Dis. 2002; 186:731–736.
Jenson, H. B. Epstein-Barr virus. Pediatr Rev, 2011; 32: 375–383.
Arotiba JT, Adebola AR, Iliyasu Z, Babashan M, Ladipo MMA, Osude OD et al. Oral manifestations of HIV/AIDS infection in Nigerian patients. Nigerian Journal of Surgical Research, 2005; 7, 176-181
Chakraborty N, Bhattacharyya S, de Mukherjee CA, Bhattacharya D, Santra S, Chakrabarti. S et al. Incidence of multiple herpesvirus Infection in HIV seropositive patients, a big concern for Eastern Indian scenario. Virology Journal, 2010; 7, 147: 1-7
Abdollahi A, Shoar S, Rasoulinejad M, Sheikhbahaei. S Sero-prevalence of Epstein - Barr virus among HIV positive patients moreover and its association with CD4 positive lymphocyte count. Acta Medica Iranica, 2014; 52(12), 916-921
Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, Asare I. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis, 2008; 8: 111.
Wagner HJ, Hornef M, Teichert HM, Kirchner H. Sex difference in the serostatus of adults to the Epstein-Barr virus. Immunobiology, 1994; 190: 424-429
Balfour HHJr, Odumade OA, Schmeling DO, Knight JA, Vezina HE, Hogquist KA et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis, 2013; 207: 80–88.